ArticleStroke (Hoboken, N.J.)2026
Adjusting Antiplatelet Therapy Using P2Y
Article in Stroke (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe effectiveness of platelet reactivity unit (PRU)-guided individualized antiplatelet therapy for intracranial aneurysm treatment remains uncertain.
methodsThis retrospective study evaluated 1705 patients with 1883 unruptured intracranial aneurysms who received endovascular treatments at a tertiary center between March 2018 and December 2020. Patients were divided into 2 groups: a standard group (aspirin and clopidogrel without PRU) and an individualized group where antiplatelet therapy was adjusted or switched to low-dose prasugrel based on preprocedural PRU values by VerifyNow. In the individualized group, hyporesponsiveness was defined as PRU>238 or inhibition <26%, prompting transition to low-dose prasugrel, whereas hyperresponsiveness was defined as PRU<86 or inhibition >74%, leading to dose withholding. The primary outcome was thromboembolic and hemorrhagic complications within 1 month. Thromboembolic complications included intraprocedural thrombosis, transient ischemic attack, and ischemic stroke confirmed on diffusion-weighted imaging; microembolism was defined as acute diffusion-weighted imaging lesions <1 cm. Hemorrhagic complications encompassed intracranial bleeding and extracranial access site hematomas (retroperitoneal hematoma, puncture-site pseudoaneurysm). Functional outcomes were assessed using the modified Rankin Scale. Subgroup analyses were performed for complex procedures, defined as stent-assisted coiling and flow diversion.
resultsAverage patient age was 58.0±10.8 years; 72.4% were female. The cohort included 1020 patients in the standard group and 685 in the individualized group. No significant difference in overall thromboembolic complications was observed between the standard (2.4%) and individualized groups (1.3%;
conclusionsIndividualized antiplatelet therapy based on PRU measurements did not impact overall outcomes but reduced ischemic complications in complex endovascular treatments without increasing bleeding risks. Further validation is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.